相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Accessibility of Low-cost Insulin From Illegitimate Internet Pharmacies: Cross-sectional Study
Benjamin Penley et al.
JOURNAL OF MEDICAL INTERNET RESEARCH (2022)
Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis
Li-Jou Yang et al.
BMC ENDOCRINE DISORDERS (2022)
Use of Biosimilar Medications in Oncology
Zeina Nahleh et al.
JCO ONCOLOGY PRACTICE (2022)
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
Neelima Denduluri et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
Viral N. Shah et al.
DIABETES THERAPY (2021)
Day-to-day variability of insulin requirements in the inpatient setting: Observations during fully closed-loop insulin delivery
Charlotte K. Boughton et al.
DIABETES OBESITY & METABOLISM (2021)
Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market
Joseph Levy et al.
JAMA INTERNAL MEDICINE (2021)
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study
Mirian Brink et al.
BLOOD ADVANCES (2021)
Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
Nana Bernasko et al.
CROHNS & COLITIS 360 (2021)
Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
Nana Bernasko et al.
CROHNS & COLITIS 360 (2021)
US rheumatologists' beliefs and knowledge about biosimilars: a survey
Allan Gibofsky et al.
RHEUMATOLOGY (2021)
Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
Valentina Shakhnovich et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
The Evolution of Insulin and How it Informs Therapy and Treatment Choices
Irl B. Hirsch et al.
ENDOCRINE REVIEWS (2020)
Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.
Xavier Pivot et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Biologic Drug Quality Assurance to Optimize HER2+Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
Diana Luftner et al.
TARGETED ONCOLOGY (2020)
Clinical and Regulatory Concerns of Biosimilars: A Review of Literature
Vesa Halimi et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis
Majid Mobasseri et al.
HEALTH PROMOTION PERSPECTIVES (2020)
Biosimilars: what the oncologist should know
Marc Thill et al.
FUTURE ONCOLOGY (2019)
Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018
Inmaculada Hernandez et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
Byong Duk Ye et al.
LANCET (2019)
Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals
Laurence Greene et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2019)
Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey
Laurent Peyrin-Biroulet et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis
Sanjay Basu et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Philip Home et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2018)
The nocebo effect challenges the non-medical infliximab switch in practice
N. W. Boone et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Xavier Pivot et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Science Behind Biosimilars Entering a New Era of Biologic Therapy
S. Louis Bridges et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Rationale, Opportunities, and Reality of Biosimilar Medications
George Y. Tang
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review
Emily Leonard et al.
Journal of Managed Care & Specialty Pharmacy (2018)
Inflammatory Bowel Disease: Complexity and Variability Need Integration
Claudio Fiocchi
FRONTIERS IN MEDICINE (2018)
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Lars Erik Kristensen et al.
BIODRUGS (2018)
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
Hillel Cohen et al.
ADVANCES IN THERAPY (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice
Jennifer Goldman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Efficacy and Safety of Biosimilar*SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study
Satish K. Garg et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2017)
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Administration of Biosimilar Insulin Analogs: Role of Devices
Lutz Heinemann et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2017)
Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents
Balazs Vezer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Variability of Insulin Requirements Over 12 Weeks of Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes
Yue Ruan et al.
DIABETES CARE (2016)
The nocebo effect of drugs
Sara Planes et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2016)
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus (R)) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2015)
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
T. C. Blevins et al.
DIABETES OBESITY & METABOLISM (2015)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Nocebo Effects, Patient-Clinician Communication, and Therapeutic Outcomes
Luana Colloca et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Epoetin-associated pure red cell aplasia: past, present, and future considerations
June M. McKoy et al.
TRANSFUSION (2008)
分享论文
